Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone and Bexarotene in CTCL
NCT00178841Phase 2Completed
- Sponsor
- Vanderbilt University
- Start
- Jun 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rosiglitazone in cutaneous T-cell lymphoma (CTCL), sponsored by Vanderbilt University. Primary endpoint: Number of Participants With a 50% Improvement in Baseline Skin Score at 16 weeks. Started Jun 2005; status: completed.
02
Drugs
rosiglitazone
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00178841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00178841.